dual agonist glp 1 glucagon Effects, working principles and target tissues of agonists Designing a dual GLP-1R/GIPR agonist

In addition, it is difficult to apply the results of this study to humans because it is not common to administer GLP-1RA under fasting conditions in humans

This state-of-the-art narrative review synthesizes current evidence from clinical trials, pharmacovigilance databases, and real-world cohorts to provide a comprehensive evaluation of the safety and tolerability of GLP-1RAs and tirzepatide

Breast adenocarcinoma Prostate adenocarcinoma Non-small cell lung cancer (NSCLC) Colorectal adenocarcinoma Hepatocellular carcinoma (liver cancer) Renal cell carcinoma Pancreatic adenocarcinoma Half of the participants started a GLP-1 medication semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide or pramlintide after their cancer diagnosis

The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors

Clinicians are also cautious about prescribing these drugs to individuals with a history of eating disorders, where appetite suppression and weight loss may trigger relapse

ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Deacon CF, Holst JJ, et al